{"id":81789,"date":"2026-06-11T19:54:05","date_gmt":"2026-06-11T19:54:05","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/81789\/"},"modified":"2026-06-11T19:54:05","modified_gmt":"2026-06-11T19:54:05","slug":"hansoh-chugai-ink-separate-and-lucrative-licensing-agreements","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/81789\/","title":{"rendered":"Hansoh, Chugai ink separate and lucrative licensing agreements"},"content":{"rendered":"<p>A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China\u2019s Hansoh Pharma and California-based Rani Therapeutics, which together represent billions in potential future payouts.<\/p>\n<p>First up, the Hansoh accord: On Friday, the company <a href=\"https:\/\/staticpacific.blob.core.windows.net\/press-releases-attachments.\/3930167\/HKEX-EPS_20251017_11882001_0.PDF\" rel=\"nofollow noopener\" target=\"_blank\">announced<\/a> (PDF) on the Hong Kong Stock Exchange that it struck a deal with Roche\u2014worth up to $1.45 billion biobucks\u2014to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental CDH17-targeted antibody-drug conjugate (ADC), dubbed HS-20110.<\/p>\n<p>The agreement excludes rights to the ADC asset in mainland China, Hong Kong, Macau and Taiwan, according to Hansoh\u2019s filing. As part of the deal, Roche will hand Hansoh $80 million upfront, with up to $1.45 billion in milestone and royalty payments also on the line.<\/p>\n<p>Hansoh\u2019s ADC candidate is being developed to treat colorectal cancer and other solid tumors and is currently in phase 1 testing in China and the U.S.\u00a0<\/p>\n<p>Roche is no stranger to the colorectal cancer space, having won a nod in that indication for its IgG1 antibody Avastin (bevacizumab) back in 2004.<\/p>\n<p>&#8220;There are features that I think Hansoh has done with this molecule that made it very attractive for us,\u201d Charlie Fuchs, M.D., Roche\u2019s global head of oncology and hematology drug development, told Fierce Biotech on Friday. \u201cI think we went through a number of efforts to validate the technology and the molecule itself, and we&#8217;re really pleased to have it now in our portfolio.&#8221;<\/p>\n<p>The Roche tie-up is the latest in a string of high-profile\u2014and often lucrative\u2014licensing pacts drafted by Hansoh. In more recent months, several of those deals have focused on GLP-1s for obesity, as in the case of the $2 billion agreement between Hansoh and Regeneron that was <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/regeneron-pens-2b-pact-hansohs-potential-rival-zepbound\" rel=\"nofollow noopener\" target=\"_blank\">announced<\/a> in June.<\/p>\n<p>On the ADC front specifically, Hansoh itself <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/hansoh-fresh-big-pharma-interest-signs-690m-adc-pact-fellow-chinese-biotech-biotheus\" rel=\"nofollow noopener\" target=\"_blank\">secured a license<\/a> to use Biotheus\u2019 anti-EGFR\/cMet bispecific antibody in its development of ADCs last March. That deal puts Biotheus in the running to receive 5 billion Chinese yuan (at the time worth around $690 million) in combined upfront and success-based milestone payments, plus tiered royalties on sales of any potential ADCs Hansoh successfully commercializes.<\/p>\n<p>Rani cuts in<br \/>\u00a0<\/p>\n<p>Apart from Hansoh, Rani Therapeutics also got in on the licensing action this week, teaming up with Japanese drugmaker Chugai Pharmaceutical in a deal that could net the San Jose biotech a total of nearly $1.09 billion.<\/p>\n<p>In an interesting coincidence, Roche is the <a href=\"https:\/\/www.chugai-pharm.co.jp\/english\/ir\/share\/ownership.html\" rel=\"nofollow noopener\" target=\"_blank\">primary shareholder<\/a> in Tokyo-based Chugai.<\/p>\n<p>The collaboration and licensing deal will see Rani wed its oral delivery technology, dubbed the RaniPill, with an experimental Chugai rare disease antibody, according to an Oct. 17 <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/10\/17\/3168550\/0\/en\/Rani-Therapeutics-Announces-up-to-1-085-Billion-Collaboration-with-Chugai-Pharmaceutical-Co-for-Multiple-High-Value-Therapeutics-Including-Rare-Disease-and-Immunology-Programs-and-.html\" rel=\"nofollow noopener\" target=\"_blank\">press release<\/a>.<\/p>\n<p>Rani <a href=\"https:\/\/www.ranitherapeutics.com\/technology\/\" rel=\"nofollow noopener\" target=\"_blank\">pitches<\/a> its delivery tech as a robotic pill for biologics that moves fully intact through the stomach\u2014where acids typically break down drugs\u2014before reaching the intestine. There, the RaniPill is designed to deliver a therapeutic payload through a painless transenteric injection, according to the biotech\u2019s website.<\/p>\n<p>Breaking down the agreement, Rani will receive $10 million upfront to provide access to its pill technology, with the potential to snare up to $75 million in success-based tech transfer and development milestones down the line. The deal also covers up to $100 million in potential sales-based milestones, as well as single-digit royalties if Chugai\u2019s RaniPill-backed rare disease med goes to market.<\/p>\n<p>The agreement could be worth even more if Chugai exercises its option to extend rights to up to five additional drug targets, Rani explained, noting that those additional targets would be covered under \u201csimilar deal terms.\u201d<\/p>\n<p>\u201cRani&#8217;s innovative oral delivery technology opens up new possibilities for the administration of biologics, which have traditionally been limited to injections,\u201d Tomoyuki Igawa, Ph.D., head of Chugai\u2019s research division, said in a statement. \u201cBy integrating Rani&#8217;s technology with our proprietary antibody engineering technologies cultivated over many years, we expect to create entirely new value in the form of oral therapies that are less burdensome for patients.\u201d<\/p>\n<p>The partners did not specify which rare disease they are targeting with the collaboration.<\/p>\n<p>Simultaneously, Rani revealed that it has entered a securities purchase agreement for a private placement that it expects to net roughly $60.3 million. The placement will be led by Samsara BioCapital, alongside a mix of new and returning investors like RA Capital Management, Anomaly, Special Situations Funds, Invus, and Rani\u2019s founder and chair Mir Imran, the company said Friday.<\/p>\n<p>With the proceeds from the private placement and expected initial payouts from the Chugai deal, Rani says it believes it will have enough cash to fund its operations into 2028.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China\u2019s Hansoh Pharma&hellip;\n","protected":false},"author":2,"featured_media":81790,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[405,190,42233,1115,351,25942,29825,3772,19767,9275,42231,1219,41515,26930,42232,2421,134,8792,74],"class_list":["post-81789","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-antibody-drug-conjugates","tag-asia","tag-biologics","tag-biotech","tag-china","tag-chugai-pharmaceutical","tag-colorectal-cancer","tag-deals","tag-drug-delivery","tag-fierce-biotech-homepage","tag-hansoh-pharma","tag-japan","tag-licensing-deals","tag-milestones","tag-rani-therapeutics","tag-rare-diseases","tag-roche","tag-royalties","tag-united-states"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116733232243466637","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=81789"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/81789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/81790"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=81789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=81789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=81789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}